Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Provenge Decision Addresses Treatment Eligibility Criteria

This article was originally published in The Pink Sheet Daily

Executive Summary

The final national coverage decision confirms that Provenge will be covered for its labeled uses and that off-label use will be left to the discretion of local administrative claims contractors.
Advertisement

Related Content

Provenge, Jevtana Covered Without PA By Nearly 50% Of Payers In Analysis
Provenge, Jevtana Covered Without PA By Nearly 50% Of Payers In Analysis
Provenge Medicare NCD Needs More Clarity To Avoid Restrictions, CMS Told

Topics

Advertisement
UsernamePublicRestriction

Register

PS072457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel